Healthcare

The selected contract research organisation’s master services agreement had not been signed. The contracting target has moved from the third quarter to the fourth quarter of 2026.

CERE-CALM is randomised, double-blind and sham-controlled. It targets a minimum of 60 participants, with a planned total of 66, aged 50 or older with probable Alzheimer’s disease and behavioural and psychological symptoms of dementia.

DMX-200 is being studied in focal segmental glomerulosclerosis, a kidney disease. The adult ACTION3 Phase 3 cohort comprises 333 patients randomised and dosed across 219 sites in 21 countries.

Emyria delivers psychedelic-assisted therapy through its Empax brand using Authorised Prescribers. The report concerns treatment delivery and contains no clinical trial results.

The NextLevel OMNI device secured a Medicare PDAC billing code on 27 August 2026, with first US shipments and revenue recorded in September. CBL expects higher OMNI volumes from October onwards as the reimbursement pathway becomes available to more US providers. PRC-Saltillo trained nine …

In its quarterly activities report released on 22 October 2026, Starpharma Holdings (ASX:SPL) reported cash of $34.4 million at 30 September 2026. It also reported a pro forma cash position of $37.9 million after including a $3.5 million research and development tax incentive received …

4DMedical Limited (ASX:4DX) has released its quarterly activity report and Appendix 4C for Q1 FY27. The lung imaging technology company reported record scan volumes, revenue growth and new customer wins across the US, Europe and Australia.